Antihypertensive efficacy of zofenopril plus hydrochlorothiazide fixed combination for treatment in metabolic syndrome

Advances in Therapy

Volumn 24, Issue 5, 2007, Pages 1006-1015

  Malacco, Ettore ^a   Omboni, Stefano ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b Data Management Unit   (Italy)

Author keywords

Essential hypertension; Hydrochlorothiazide; Metabolic syndrome; Zofenopril

Indexed keywords

HYDROCHLOROTHIAZIDE; ZOFENOPRIL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MONOTHERAPY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CAPTOPRIL; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HEART RATE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED;

EID: 37249037533     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02877705     Document Type: Article

References (30)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-1428.
2. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP, for the San Antonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation. 2004;110:1251-1257.
3. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716.
4. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-689.
5. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K, for the DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004;164:1066-1076.
6. Bonora E, Targher G, Formentini G, et al. The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabet Med. 2004;21:52-58.
7. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
8. Borghi C, Ambrosioni E, for the Survival of Myocardial Infarction Long-term Evaluation-2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J. 2003;145:80-87.
9. Borghi C, Bacchelli S, Esposti DD, Bignamini A, Magnani B, Ambrosioni E, for the SMILE (Survival of Myocardial Infarction Long-term Evaluation) Study Investigators. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. Am J Hypertens. 1999;12:665-672.
10. Borghi C, Bacchelli S, Esposti DD, Ambrosioni E, for the SMILE Study. Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction. Diabetes Care. 2003;26:1862-1868.
11. Kelbaek H, Agner E, Wroblewski H, Vasehus Madsen P, Marving J. Angiotensin converting enzyme inhibition at rest and during exercise in congestive heart failure. Eur Heart J. 1993;14:692-695.
12. Binkley PF, Haas GJ, Starling RC, et al. Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. J Am Coll Cardiol. 1993;21:655-661.
13. Elijovich F, Laffer CL, Schiffrin EL. The effects of atenolol and zofenopril on plasma atrial natriuretic peptide are due to their interactions with target organ damage of essential hypertensive patients. J Hum Hypertens. 1997;11:313-319.
14. Lacourciere Y, Provencher P. Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressures in mild to moderate essential hypertension. Br J Clin Pharmacol. 1989;27:371-376.
15. Malacco E, Piazza S, Omboni S. Zofenopril versus lisinopril in the treatment of essential hypertension in elderly patients: a randomised, double-blind, multicentre study. Clin Drug Invest. 2005;25:175-182.
16. Leonetti G, Rappelli A, Omboni S, on behalf of the study group. A similar 24-h blood pressure control is obtained by zofenopril and candesartan in primary hypertensive patients. Blood Press. 2006;15(suppl 1):18-26.
17. Parati G, Omboni S, Malacco E, on behalf of the study group. Antihypertensive efficacy of zofenopril and hydrochlorothiazide combination on ambulatory blood pressure. Blood Press. 2006;15(suppl 1):7-17.
18. Zanchetti A, Parati G, Malacco E. Zofenopril plus hydrochlorothiazide: combination therapy for the treatment of mild to moderate hypertension. Drugs. 2006;66:1107-1115.
19. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific statement. Circulation. 2005;112:2735-2752.
20. Muller C, Reddert A, Wassmann S, Strehlow K, Bohm M, Nickenig G. Insulin-like growth factor induces up-regulation of AT(1)-receptor gene expression in vascular smooth muscle cells. J Renin Angiotensin Aldosterone Syst. 2000;1:273-277.
21. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol. 2002;89:3A-9A.
22. Prasad A, Quyyumi AA. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation. 2004;110:1507-1512.
23. Nickenig G, Bohm M. Interaction between insulin and ATI receptor: relevance for hypertension and arteriosclerosis. Basic Res Cardiol. 1998;93(suppl 2):135-139.
24. Deedwania PC, Volkova N. Current treatment options for the metabolic syndrome. Curr Treat Options Cardiovasc Med. 2005;7:61-74.
25. Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomised clinical trials. J Am Coll Cardiol. 2005;46:821-826.
26. Sharma AM. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension. 2004;44:12-19.
27. Singh BM, Mehta JL. Interactions between the renin-angiotensin system and dyslipidemia: relevance in the therapy of hypertension and coronary heart disease. Arch Intern Med. 2003;163:1296-1304.
28. Tykarski A. Resistant hypertension. Blood Press. 2005;2(suppl):42-45.
29. Onat A, Avci GS, Barlan MM, Uyarel H, Uzunlar B, Sansoy V. Measures of abdominal obesity assessed for visceral adiposity and relation to coronary risk. Int J Obes Relat Metab Disord. 2004;28:1018-1025.
30. Rexrode KM, Buring JE, Manson JE. Abdominal and total adiposity and risk of coronary heart disease in men. Int J Obes Relat Metab Disord. 2001;25:1047-1056.